The European Commission (EC) has granted approval for Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin).

of the non-Hodgkin lymphomas (NHL) in the United States. These types of lymphomas start in early forms of B lymphocytes (B cells). The most common types of B-cell lymphomas are listed below. Diffuse ...

Lymphomas are cancers that start in white blood cells called lymphocytes. There are 2 main types of lymphoma: Hodgkin lymphoma (HL) Non-Hodgkin lymphoma (NHL ... These cells are usually an abnormal ...

Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces the completion of ...

Explore Allogene's innovative CAR-T therapies targeting cancer & autoimmune diseases. ASCO updates on ALLO-316 could validate ...

The Nordic Protocol is a type of chemoimmunotherapy treatment. It combines chemotherapy (which aims to destroy cancer cells) ...

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

The researchers also observed significant increases in mortality for at least 1 age group for the following cancers: testicular cancer, uterine cancer, female breast cancer, bone and joint cancer, ...

LADENBURG, Germany I May 27, 2025 I Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), ...

The Changing Health Insurance Coverage Landscape in the United States Novel immunotherapies and small molecules are transforming the treatment landscape of NHLs. Anti ...

DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic ...

In an interview, Prof Martin Dreyling discussed the approval of first-line acalabrutinib for the treatment of adult patients ...